Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Immunocore HoldingsIMCR -3.83%78 Cash Ratio is 3.74 as of Jun. 2026, which is 4% below its 10-year median of 3.88. GuruFocus rates IMCR with a GF Score™ of 78/100 and a GF Value™ of $45.22 (Modestly Undervalued). The stock has 4 warning signs investors should review. Among 1,383 Biotechnology companies, Immunocore Holdings ranks better than 56.11% on this metric.
Immunocore Holdings has a Cash Ratio of 3.74. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Immunocore Holdings's Cash Ratio or its related term are showing as below:
IMCR'
s Cash Ratio Range Over the Past 10 Years
Min: 0.88 Med: 3.88 Max: 5.75
Current: 3.74
During the past 8 years, Immunocore Holdings's highest Cash Ratio was 5.75. The lowest was 0.88. And the median was 3.88.
IMCR's Cash Ratio is ranked better than 56.11% of 1383
companies
in the Biotechnology industry
Industry Median: 2.94
vs IMCR: 3.74
Immunocore Holdings (NAS:IMCR) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Immunocore Holdings Cash Ratio Related Terms
Immunocore Holdings Cash Ratio Historical Data
* Premium members only.
The historical data trend for Immunocore Holdings's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Immunocore Holdings's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Immunocore Holdings Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Immunocore Holdings's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Immunocore Holdings's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Immunocore Holdings (IMCR) has a Cash Ratio of 3.74 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Immunocore Holdings and its competitors. This is near median its historical median of 3.88. Over the past decade, Immunocore Holdings' Cash Ratio has ranged from 0.88 to 5.75. According to the industry distribution chart, Immunocore Holdings ranks #607 out of 1383 companies in the Biotechnology industry, placing it in the top 43.9%.
Is Immunocore Holdings' Cash Ratio too high?
Immunocore Holdings' current Cash Ratio of 3.74 is near median its 10-year median of 3.88. Over the past 10 years, this metric has ranged from a low of 0.88 to a high of 5.75. The Biotechnology industry median Cash Ratio is 2.94. Immunocore Holdings' value of 3.74 is 27.2% above this industry median. Based on the distribution chart, Immunocore Holdings ranks #607 out of 1383 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Immunocore Holdings has a GF Score™ of 78/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Immunocore Holdings' Cash Ratio compare to TSHA and KARD?
According to the Biotechnology industry distribution chart, Immunocore Holdings ranks #607 out of 1383 companies for Cash Ratio. This puts Immunocore Holdings in the upper half of its industry. The industry median Cash Ratio is 2.94. Immunocore Holdings' value of 3.74 is 27.2% above this benchmark. Historically, Immunocore Holdings' own Cash Ratio has ranged from 0.88 to 5.75 over the past decade. While the company's 10-year median is 3.88 vs. the industry median of 2.94, Immunocore Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 2.94, based on 1,383 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Immunocore Holdings's current Cash Ratio of 3.74 is 27.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Immunocore Holdings and its competitors. For the Biotechnology industry, the median Cash Ratio is 2.94 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Immunocore Holdings's current Cash Ratio is 3.74, which is near median its own 10-year median of 3.88. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Immunocore Holdings stock overvalued right now?
Based on GuruFocus' analysis, Immunocore Holdings (IMCR) is currently considered Modestly Undervalued. The stock's GF Value™ is $45.22, compared to a current price of $36.13 — trading 20.1% below its estimated fair value. The current Cash Ratio is 3.74, which is near median its 10-year median of 3.88 and 27.2% above the Biotechnology industry median of 2.94. Immunocore Holdings' overall GF Score™ is 78/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Immunocore Holdings (IMCR), the current Cash Ratio is 3.74 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Immunocore Holdings (IMCR) Overvalued in 2026?
Based on GuruFocus' analysis, Immunocore Holdings stock appears to be undervalued.
The current stock price of $36.13 is trading 20.1% below its estimated GF Value™ of $45.22.
GuruFocus considers Immunocore Holdings to be Modestly Undervalued.
Key valuation signals for IMCR:
Cash Ratio: 3.74 (near median its 10-year median of 3.88)
GF Value™: $45.22 vs. price of $36.13 (20.1% below fair value)
Industry Position: 27.2% above the Biotechnology median (#607 of 1383)
No single metric tells the full story. See the IMCR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Immunocore Holdings PLC is a commercial-stage biotechnology company. Using its ImmTAX platform, the company is developing a deep pipeline in multiple therapeutic areas, including clinical stage programs in oncology and infectious disease, pre-clinical programs in autoimmune disease, and earlier pre-clinical programs across three therapeutic areas. The company's main product, KIMMTRAK, is used for the treatment of unresectable or metastatic uveal melanoma (mUM). The other drug candidates in its pipeline include Brenetafusp, IMC-P115C, IMC-T119C, IMC-R117C, IMC-S118AI, IMC-U120AI, and others, being developed as a potential treatment for various oncology, infectious, and autoimmune diseases.
78GF Score
Get the complete analysis for IMCR
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IMCR has been successfully added to your 
